Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial

BACKGROUND: Several antidiabetic therapies affect bone metabolism. Sulfonylureas have the lowest impact on bone among oral antidiabetics. The objective of this study is to compare the effects of vildagliptin and gliclazide modified release (MR) on bone turnover markers (BTMs) and bone mineral densit...

Descripción completa

Detalles Bibliográficos
Autores principales: Vianna, Andre Gustavo Daher, de Lacerda, Claudio Silva, Pechmann, Luciana Muniz, Polesel, Michelle Garcia, Marino, Emerson Cestari, Borba, Victoria Zeghbi Cochenski, Barreto, Fellype de Carvalho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433032/
https://www.ncbi.nlm.nih.gov/pubmed/28515791
http://dx.doi.org/10.1186/s13098-017-0232-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433032/
https://www.ncbi.nlm.nih.gov/pubmed/28515791
http://dx.doi.org/10.1186/s13098-017-0232-2

Ejemplares similares